This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 12496 results found since Jan 2013.
Time to End Racial Disparities in Buprenorphine Access
Am J Public Health. 2023 Aug 17:e1-e3. doi: 10.2105/AJPH.2023.307388. Online ahead of print.NO ABSTRACTPMID:37590915 | DOI:10.2105/AJPH.2023.307388
Source: Am J Public Health - August 17, 2023 Category: International Medicine & Public Health Authors: Henry Rosen Chinazo O Cunningham Source Type: research
Sublingual/Buccal buprenorphine and dental problems: a pharmacovigilance study
CONCLUSIONS: Sublingual/buccal buprenorphine might increase the risk of reporting dental problems. However, these results do not modify the benefits of sublingual/buccal buprenorphine in the treatment of opioid use disorders.PMID:37584264 | DOI:10.1080/14740338.2023.2247962
Source: Expert Opinion on Drug Safety - August 16, 2023 Category: Drugs & Pharmacology Authors: Romain Barus Fran çois Montastruc Claire de Canecaude Haleh Bagheri Agn ès Sommet Maryse Lapeyre-Mestre Source Type: research
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder
CONCLUSIONS: Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women.SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.PMID:37583120 | DOI:10.1111/ajad.13463
Source: American Journal on Addictions - August 16, 2023 Category: Addiction Authors: Margaret Paschen-Wolff Shelly F Greenfield R Kathryn McHugh Kathleen Burlew Martina Pavlicova Tse-Hwei Choo Celestina Barbosa-Leiker Lesia M Ruglass Sarah Mennenga John Rotrosen Edward V Nunes Aimee N C Campbell Source Type: research
Re-Purposing FDA-Approved Drugs for Opioid Use Disorder
CONCLUSION: These results provide medication options that may be useful in treating OUD as well as integrated therapies to treat comorbid mental illness.PMID:37584436 | DOI:10.1080/10826084.2023.2247071
Source: Substance Use and Misuse - August 16, 2023 Category: Addiction Authors: Krishna Patel David Waldron Nicholas Graziane Source Type: research
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder
CONCLUSIONS: Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women.SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.PMID:37583120 | DOI:10.1111/ajad.13463
Source: The American Journal on Addictions - August 16, 2023 Category: Addiction Authors: Margaret Paschen-Wolff Shelly F Greenfield R Kathryn McHugh Kathleen Burlew Martina Pavlicova Tse-Hwei Choo Celestina Barbosa-Leiker Lesia M Ruglass Sarah Mennenga John Rotrosen Edward V Nunes Aimee N C Campbell Source Type: research
